Sakurai Haruna, Sakurai Fuminori, Kawabata Kenji, Sasaki Tomomi, Koizumi Naoya, Huang Haiying, Tashiro Katsuhisa, Kurachi Shinnosuke, Nakagawa Shinsaku, Mizuguchi Hiroyuki
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
J Control Release. 2007 Feb 26;117(3):430-7. doi: 10.1016/j.jconrel.2006.11.030. Epub 2006 Dec 9.
Vectors for gene expression are the essential tools for both gene therapy and basic research. There are two groups of gene therapy vectors, viral and non-viral vectors. At present, toxicity triggered by vectors is one of the major concerns for clinical trials. In general, non-viral vectors, such as plasmid DNA-cationic liposome complex (lipoplex), are thought to be safer than viral vectors, such as adenovirus (Ad) vector, although lipoplex is less efficient in term of gene expression than the Ad vector. However, there has been no study directly comparing the gene expression efficiency and safety of viral and non-viral vectors. Here, we present evidence that the Ad vector shows much more efficient gene expression and is safer than lipoplex, at least with respect to the innate immune response. After being systemically administered to mice, the Ad vector showed a transduction efficiency that was 2 to 5 log orders higher than that of lipoplex, depending on the organ. On the other hand, surprisingly, the administration of lipoplex produced a greater amount of inflammatory cytokines such as interleukin-6, interleukin-12, and tumor necrosis factor-alpha than did the administration of the Ad vector, whereas a comparable level of hepatotoxicity was induced by these vectors. The production of inflammatory cytokines induced by the injection of lipoplex was reduced when the CpG motifs were removed completely from plasmid DNA. Thus, care should be taken to ensure the innate immune response induced by gene therapy vectors, especially lipoplex.
基因表达载体是基因治疗和基础研究的重要工具。基因治疗载体分为两组,即病毒载体和非病毒载体。目前,载体引发的毒性是临床试验的主要关注点之一。一般来说,非病毒载体,如质粒DNA - 阳离子脂质体复合物(脂质体转染复合物),被认为比病毒载体,如腺病毒(Ad)载体更安全,尽管脂质体转染复合物在基因表达方面的效率低于Ad载体。然而,尚未有研究直接比较病毒载体和非病毒载体的基因表达效率和安全性。在此,我们提供证据表明,至少在先天免疫反应方面,Ad载体显示出更高的基因表达效率且比脂质体转染复合物更安全。经全身给药至小鼠后,根据器官不同,Ad载体的转导效率比脂质体转染复合物高2至5个对数级。另一方面,令人惊讶的是,与Ad载体给药相比,脂质体转染复合物给药产生了更多的炎性细胞因子,如白细胞介素 - 6、白细胞介素 - 12和肿瘤坏死因子 - α,而这些载体诱导的肝毒性水平相当。当从质粒DNA中完全去除CpG基序时,脂质体转染复合物注射诱导的炎性细胞因子产生减少。因此,应注意确保基因治疗载体,特别是脂质体转染复合物诱导的先天免疫反应。